Market Overview

Rodman & Renshaw Maintains NxStage Medical Market Perform

Rodman & Renshaw maintained its NxStage Medical (NASDAQ: NXTM) Market Perform rating in a research report published today.

In the report, Rodman & Renshaw states, "Given the risks we see on the horizon, [NXTM] is fairly valued at the current levels. We believe the key risks to this story are execution risk, reimbursement risk and market risk."

Shares of NXTM closed today at $19,78, down 11.78% from Wednesday's market close.

Posted-In: Analyst Color Analyst Ratings

 

Most Popular

Related Articles (NXTM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters